Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF
August 3, 2009
- Can You Tell a Good Story?
August 3, 2009
- Doctors' Sources of Information on ARBs Investigated by So-net M3
August 3, 2009
- Medical Expenditures Up 1.9% to ¥34.1 Tril. In FY2008
August 3, 2009
- Eisai Submits First Application for E7389 in Switzerland
August 3, 2009
- Only 40% of Consumers Have Single Regular Pharmacies: JPA
August 3, 2009
- FDA Extends NDA Review for Alogliptin and ACTOS Combination
August 3, 2009
- Isentress Should Be Used in First-Line Therapy: Dr Hanabusa
August 3, 2009
- Sitagliptin, Sibutramine Recommended for Approval
August 3, 2009
- Exceptional NHI Price Maintenance System Benefits Patients: Mr Nagano
August 3, 2009
- Generics, Drug Pricing Not Included in DPJ's Manifesto
August 3, 2009
- REGULATORY NEWS IN BRIEF
August 3, 2009
- NHI Price Listing Expected for 46 Generics for Sarpogrelate from 23 Companies
July 27, 2009
- Nichi-Iko to Enter US Market in 2012
July 27, 2009
- Sales of Ethical Drugs Down 1.6% in May: Crecon
July 27, 2009
- REGULATORY NEWS IN BRIEF
July 27, 2009
- NDA for Sitagliptin to Be Reviewed
July 27, 2009
- Points at Issue Proposed by Korosho Regarding NHI Price Maintenance System
July 27, 2009
- DPO Proposes New Pricing Rule for Combination Drugs
July 27, 2009
- Question Raised Again on Need for Exceptional Price Maintenance System
July 27, 2009
ページ
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…